Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.53 |
| ▸ | TGFBR2 | P37173 | 9/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551847 | 0.91 | TGFBR1 (0.51) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL2396089 | 0.91 | TGFBR1 (0.51) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL2210408 | 0.87 | TGFBR1 (0.53) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL2491506 | 0.86 | TGFBR1 (0.54) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL2394051 | 0.86 | TGFBR1 (0.72) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL2210473 | 0.85 | NUDT1 (0.56) | TGFBR1PRKD3PRKD1PRKD2PIM1 | |
| SCHEMBL14564461 | 0.85 | TGFBR1 (0.56) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL5551403 | 0.85 | TGFBR1 (0.74) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL14564462 | 0.82 | BUB1 (0.48) | TGFBR1PRKD3PRKD1PRKD2 | |
| SCHEMBL2394048 | 0.81 | ABCG2 (0.52) | TGFBR1PRKD3PRKD1PRKD2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096333-A1 | Quinazoline derivatives as medicaments | HRH4, HRH2, HRH3 | TGFBR1 70/4885PRKD3 3011/4885PRKD1 3332/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | TGFBR1 8/4885PRKD3 1661/4885PRKD1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.